These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2571616)

  • 41. Alpha 1-blockers in hypertension.
    Sever PS
    Curr Med Res Opin; 1999; 15(2):95-103. PubMed ID: 10494492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism.
    Nash DT
    Clin Cardiol; 1990 Nov; 13(11):764-72. PubMed ID: 1980236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
    Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antihypertensive therapy in the geriatric patient: II. A review of the alpha1-adrenergic blocking agents.
    Studer JA; Piepho RW
    J Clin Pharmacol; 1993 Jan; 33(1):2-13. PubMed ID: 8094084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
    Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
    Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
    Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The value of alpha-blockers in the management of hypertension: a practical view.
    McInnes GT
    J Hum Hypertens; 1991 Aug; 5(4):313-6. PubMed ID: 1683406
    [No Abstract]   [Full Text] [Related]  

  • 49. A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.
    Taylor SH; Lee PS; Sharma SK
    Am Heart J; 1988 Dec; 116(6 Pt 2):1820-5. PubMed ID: 2904757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beneficial effect of alpha-blocker on hemorheology in patients with essential hypertension.
    Gomi T; Ikeda T; Ikegami F
    Am J Hypertens; 1997 Aug; 10(8):886-92. PubMed ID: 9270083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alpha- and beta-receptor blocking drugs in the treatment of hypertension.
    Ram CV; Kaplan NM
    Curr Probl Cardiol; 1979 Jan; 3(10):1-53. PubMed ID: 40755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism.
    Ferrara LA; Marotta T; Rubba P; De Simone B; Leccia G; Soro S; Mancini M
    Am J Med; 1986 Feb; 80(2A):104-8. PubMed ID: 2868656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL
    Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
    Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS
    J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
    Bartels AC; de Vries PM; Oe LP; van Bronswÿk H; Donker AJ; Réveillaud RJ; Fillastre JP; Zech P
    Am Heart J; 1988 Dec; 116(6 Pt 2):1772-7. PubMed ID: 2904749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist.
    de Leeuw PW; Ligthart JJ; Smout AJ; Birkenhäger WH
    Eur J Clin Pharmacol; 1982; 23(5):397-401. PubMed ID: 6129979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacology of antihypertensive drugs with special reference to vasodilators, alpha-adrenergic blocking agents and prazosin.
    Cambridge D; Davey MJ; Massingham R
    Med J Aust; 1977 Aug; 2(1 Suppl):2-6. PubMed ID: 21341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.